International Journal of Advance and Applied Research
Peer Reviewed | International Open Access Journal
ISSN: 2347-7075 | Impact Factor – 8.141 | *Website: https://ijaar.co.in/*
Volume-13, Issue-2 | November - December 2025

Original Article

STUDY OF ORGANIC AND INORGANIC COMPOUNDS FOR THE TREATMENT OF CANCER

Dr. Bishnu Shanker Dubey
Assistant Professor, Department of Chemistry,
Veer Kunwar Singh College Dharupur Bikramganj
(Affiliated unit of V.K.S. University Ara, Bhojpur, Bihar)

Manuscript ID: IJAAR-130226

ISSN: 2347-7075
Impact Factor – 8.141

Volume - 13
Issue - 2
November - December 2025
Pp. 167 - 171

Submitted: 21 Dec 2025
Revised: 29 Dec 2025
Accepted: 31 Dec 2025
Published: 1 Jan 2026

Corresponding Author:
Dr. Bishnu Shanker Dubey

Quick Response Code:

Website: https://ijaar.co.in/

DOI: 10.5281/zenodo.18654010

DOI Link: https://doi.org/10.5281/zenodo.18654010

Creative Commons

OPEN ACCESS

Abstract:

Cancer remains one of the leading causes of mortality worldwide, accounting for nearly 10 million deaths in 2022 according to the World Health Organization. The disease is characterized by uncontrolled cellular proliferation, genetic mutations, evasion of apoptosis, angiogenesis, and metastatic progression. Over the past seven decades, both organic and inorganic compounds have played a transformative role in cancer therapy. Organic anticancer agents include alkylating agents, antimetabolites, natural product derivatives, targeted small molecules, and monoclonal antibodies. Inorganic compounds, particularly metal-based drugs such as platinum, ruthenium, gold, and titanium complexes, have demonstrated significant therapeutic efficacy through mechanisms such as DNA crosslinking, redox modulation, and apoptosis induction.

This paper presents a comprehensive comparative study of organic and inorganic compounds used in cancer treatment. It explores their chemical structures, mechanisms of action, pharmacodynamics, resistance mechanisms, clinical efficacy, toxicity profiles, and future therapeutic potential. The integration of nanotechnology, personalized medicine, and metal-organic hybrid complexes is also discussed as a promising direction for next-generation anticancer therapeutics.

Keywords: Cancer therapy, Organic anticancer drugs, Metal-based drugs, Cisplatin, Targeted therapy, Chemotherapy, Nanomedicine, Drug resistance, Platinum complexes

Creative Commons (CC BY-NC-SA 4.0)

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), *which permits others to remix, adapt, and build upon the work non-commercially, provided that appropriate credit is given and that any new creations are licensed under identical terms.*

How to cite this article:

Dr. Bishnu Shanker Dubey. (2025). Study Of Organic And Inorganic Compounds For The Treatment Of Cancer. International Journal of Advance and Applied Research, 13(2), 167–171. https://doi.org/10.5281/zenodo.18654010

International Journal of Advance and Applied Research
Peer Reviewed | International Open Access Journal
ISSN: 2347-7075 | Impact Factor – 8.141 | *Website:* https://ijaar.co.in/
Volume-13, Issue-2 | November - December 2025

Introduction:

Cancer is a complex, multistep genetic disease resulting from the accumulation of mutations in oncogenes, tumor suppressor genes, and DNA repair genes. It is not a single disease but a collection of over 200 distinct disorders affecting various tissues and organs.

According to global cancer statistics:

- Approximately 20 million new cancer cases were diagnosed worldwide in 2022.
- Lung cancer accounts for the highest mortality rate globally.
- Breast cancer remains the most commonly diagnosed cancer.

1. Molecular Hallmarks of Cancer:

Hanahan and Weinberg (2000; 2011) described the "Hallmarks of Cancer," which include:

- Sustained proliferative signaling
- Evading growth suppressors
- Resistance to cell death
- Replicative immortality
- Induction of angiogenesis
- Activation of invasion and metastasis
- Deregulated cellular energetics
- Immune evasion

Modern anticancer drugs are designed to target one or more of these hallmarks.

Research Methodology:

This study is based on a systematic review of secondary data sources.

1. Data Sources:

- PubMed and ScienceDirect databases
- WHO Global Cancer Reports
- FDA drug approval records
- Nature Reviews Cancer
- Journal of Medicinal Chemistry

2. Analytical Approach:

- Comparative pharmacological analysis
- Structural and mechanistic evaluation
- Clinical outcome assessment
- Toxicity and resistance evaluation

Organic Compounds in Cancer Therapy:

Organic compounds form the foundation of traditional chemotherapy and modern targeted therapy.

1. Alkylating Agents:

Examples:

- Cyclophosphamide
- Melphalan
- Ifosfamide

Mechanism of Action:

Alkylating agents transfer alkyl groups to DNA bases, primarily at the N7 position of guanine. This results in:

- DNA cross-linking
- Strand breakage
- Inhibition of replication
- Apoptosis induction

Clinical Applications:

Used in lymphomas, leukemias, breast cancer, and ovarian cancer.

Limitations:

- Bone marrow suppression
- Secondary malignancies
- Drug resistance via enhanced DNA repair

2. Antimetabolites:

These drugs mimic natural metabolites and interfere with DNA synthesis.

International Journal of Advance and Applied Research
Peer Reviewed | International Open Access Journal
ISSN: 2347-7075 | Impact Factor – 8.141 | *Website:* https://ijaar.co.in/
Volume-13, Issue-2 | November - December 2025

- Methotrexate
- Inhibits dihydrofolate reductase (DHFR)
- Blocks thymidine synthesis
- Used in leukemia and osteosarcoma
- 5-Fluorouracil (5-FU)
- Inhibits thymidylate synthase
- Effective in colorectal cancer

3. Natural Product-Derived Compounds:

- Paclitaxel (Taxol)
- Stabilizes microtubules
- Prevents mitotic spindle disassembly
- Used in ovarian and breast cancer
- Vincristine
- Inhibits microtubule polymerization
- Used in leukemia

These agents originate from plant sources (e.g., Taxus brevifolia).

4. Targeted Small Molecules:

- Imatinib
- Inhibits BCR-ABL tyrosine kinase
- Revolutionized treatment of Chronic Myeloid Leukemia (CML)
- Achieves >90% 5-year survival in early-stage CML
- Erlotinib
- EGFR inhibitor
- Used in non-small cell lung cancer

Targeted therapies reduce systemic toxicity compared to traditional chemotherapy.

5. Monoclonal Antibodies:

- Trastuzumab
- Targets HER2 receptor
- Improves survival in HER2-positive breast cancer
- Rituximab
- Targets CD20 antigen
- Used in Non-Hodgkin Lymphoma

These biologics activate immune-mediated cytotoxicity.

Inorganic Compounds in Cancer Therapy:

Metal-based drugs represent a major class of inorganic anticancer agents.

1. Platinum-Based Drugs:

Cisplatin ($Pt(NH_3)_2Cl_2$) Discovered in 1965 by Barnett Rosenberg.

Mechanism:

- Forms intra-strand DNA crosslinks
- Distorts DNA helix
- Activates apoptosis pathways

Clinical Impact:

- Testicular cancer cure rate exceeds 95% in early stages
- Used in lung, bladder, ovarian cancers

Toxicity:

- Nephrotoxicity
- Ototoxicity
- Neurotoxicity
- Carboplatin
- Reduced nephrotoxicity
- Preferred in ovarian cancer
- Oxaliplatin
- Effective in colorectal cancer
- Causes peripheral neuropathy

2. Ruthenium Complexes:

Ruthenium compounds (e.g., NAMI-A, KP1019) are under clinical investigation.

Advantages:

- Lower systemic toxicity
- Preferential activation in hypoxic tumor environments
- Redox-active behavior

International Journal of Advance and Applied Research
Peer Reviewed | International Open Access Journal
ISSN: 2347-7075 | Impact Factor – 8.141 | *Website:* https://ijaar.co.in/
Volume-13, Issue-2 | November - December 2025

3. Gold-Based Compounds:

Auranofin:

- Inhibits thioredoxin reductase
- Induces oxidative stress
- Shows promise in leukemia research

4. Titanium and Gallium Complexes:

These experimental agents interfere with DNA binding and iron metabolism.

Comparative Analysis:

- Parameter
- Organic Compounds
- Inorganic Compounds
- Chemical Nature
- Carbon-based
- Metal-centered
- Target Specificity
- Often high
- DNA-focused
- Toxicity
- Moderate to high
- Often organ-specific
- Resistance
- Common
- Also significant
- Clinical Maturity
- Highly developed
- Limited but powerful

Drug Resistance Mechanisms:

Cancer cells develop resistance through:

- Increased drug efflux (P-glycoprotein pumps)
- Enhanced DNA repair mechanisms
- Mutation of target proteins
- Tumor microenvironment adaptation

Overcoming resistance is a major research priority.

Nanotechnology in Cancer Therapy

Nanomedicine improves drug delivery efficiency.

- Liposomal Doxorubicin (Doxil)
- Reduced cardiotoxicity
- Improved tumor targeting
- Gold Nanoparticles
- Used in photothermal therapy
- Localized tumor destruction

Nanocarriers enhance bioavailability and reduce systemic toxicity.

Emerging Trends:

- Metal-organic hybrid complexes
- Combination therapy (e.g., Cisplatin + Immunotherapy)
- AI-driven drug discovery
- Personalized genomic profiling

Discussion:

Organic compounds offer structural diversity and target specificity, forming the backbone of chemotherapy and targeted therapy. Inorganic compounds, particularly platinum-based drugs, demonstrate powerful cytotoxic effects through direct DNA interaction.

Future therapeutic strategies may integrate both categories into hybrid systems that maximize selectivity and minimize toxicity.

Conclusion:

The treatment of cancer relies heavily on both organic and inorganic compounds. Organic drugs provide versatility and target specificity, while inorganic metal-based drugs deliver potent

DNA-damaging effects. Advances in nanotechnology, molecular biology, and computational drug design are shaping the future of oncology.

An integrated approach combining chemistry, molecular biology, and clinical research will be essential for developing safer and more effective anticancer therapies.

References:

1. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer. Cell.
2. Rosenberg, B. (1965). Platinum compounds in cancer therapy. Nature.
3. Chabner, B. A., & Roberts, T. G. (2005). Chemotherapy and the war on cancer. Nature Reviews Cancer.
4. Johnstone, T. C., et al. (2016). The next generation of platinum drugs. Chemical Reviews.
5. WHO Global Cancer Report (2022).
6. DeVita, V. T., et al. Cancer: Principles & Practice of Oncology.
7. Ott, I., & Gust, R. (2007). Non-platinum metal complexes as anticancer agents. Archives of Pharmacal Research.